Nuvation Bio, a development-stage oncology company, focuses on the clinical development for the treatment of cancer. The companies lead drug Taletrectinib, an orally available inhibitor is currently being reviewed by the FDA for Advanced ROS1+NSCLC, with a decision date (PDUFA) of June 23rd.
Financial Statistics:
- $461 million cash
- Debt - minimal
- 340 million diluted shares outstanding
- 782 million market cap
Intellectual Property:
- Taletrectinib - Expected to expire from 2033 to 2042
- Safusidenib - Expected to expire from 2035 to 2041
Timeline Catalyst:
- Taletrectinib: FDA approval decision June 23, 2025
- Safusidenib: Begin pivotal phase 3 for diffuse IDH1-mutant glioma, 2025
No comments:
Post a Comment